View More
In this commentary, 2 experts discuss the potential for PARP inhibitor combinations as neoadjuvant therapy and in the setting of metastatic castration-sensitive disease.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.